Cara Therapeutics, Inc. Reports Positive Phase II Data for Novel Peripheral Analgesic in Acute Post-Operative Pain
2/8/2010
More...
|
Resverlogix Corporation (RVX.TO) Completes Patient Recruitment for ASSERT Trial
2/8/2010
More...
|
Kamada Ltd. Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe
2/8/2010
More...
|
U.S. FDA Staff Questions Small ChemGenics Pharmaceuticals Study
2/8/2010
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report Elevated Levels of Tß4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
2/8/2010
More...
|
Genta Incorporated (GETA.OB) Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
2/8/2010
More...
|
Solace Pharmaceuticals Closes Boston-Area Office After Pain Treatment Fails in Clinical Trial
2/8/2010
More...
|
Drexel University College Of Medicine and Hahnemann Hospital Start Phase II Clinical Trial of Osiris Therapeutics, Inc. (OSIR) Prochymal
2/5/2010
More...
|
Clinical Trial Delays Hit Lipoxen (LPX.L) Revenues
2/5/2010
More...
|
AVI BioPharma, Inc. (AVII)'s Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystrophy
2/5/2010
More...
|
ArQule, Inc. (ARQL) Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer
2/4/2010
More...
|
Health Decisions Exceeds Goals for Universal Flu Vaccine Study
2/4/2010
More...
|
First Clinical Trial on Nitroglycerin to Treat Prostate Cancer Shows Potential to Halt Disease, Queen’s University Research Shows
2/4/2010
More...
|
Vertex Pharmaceuticals (MA) (VRTX) Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis
2/3/2010
More...
|
Amarillo Biosciences (AMAR) Announces Preliminary Results That Indicate Influenza-Like Illness Incidence Reduced From 71% to 43% in Vaccinated Patients Treated With Oral Interferon, Symptoms Also Lessened
2/3/2010
More...
|
Hybrigenics Receives Positive Answers From European Medicines Evaluation Agency on Clinical Phase IIb Efficacy Study
2/3/2010
More...
|
Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
2/2/2010
More...
|
Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-101, Potent Small Molecule For Treatment Of Alzheimer's Disease And Anxiety
2/2/2010
More...
|
Ark Therapeutics: First Refractory Angina Patient Treated with VEGF-D shortform (EG011) in Phase I/IIa Trial
2/2/2010
More...
|
Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson's Disease
2/1/2010
More...
|
Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders
2/1/2010
More...
|
Conatus Pharmaceuticals Inc. Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
1/29/2010
More...
|
AEterna Zentaris (AEZS) Partner Keryx Biopharmaceuticals (KERX) Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
1/29/2010
More...
|
Omeros Corporation Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
1/29/2010
More...
|
Lipid Therapeutics Announces Start of Phase IIb Clinical Trial
1/29/2010
More...
|
Omeros Corporation Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
1/28/2010
More...
|
Allon Therapeutics, Inc. Initiates Trial to Expand Safety Profile for Dementia Drug Davunetide
1/28/2010
More...
|
Stem Cell Therapeutics (SSS.V) Receives 'No Objection Letter' From Health Canada for the Phase IIa Clinical Trial in Traumatic Brain Injury Patients
1/28/2010
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI) to End Development of Enlarged-Prostate Drug; To Save More Than $40 Million from Termination
1/27/2010
More...
|
Lexicon Pharmaceuticals, Inc. (LXRX) to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
1/27/2010
More...
|
Supernus Pharmaceuticals Announces Positive Results from Phase IIa Clinical Trial for SPN 810 in Children with ADHD and Serious Conduct Problems
1/27/2010
More...
|
YM BioSciences (YM.TO) Announces FDA Clearance for Two Ongoing Phase II Nimotuzumab Trials into USA
1/26/2010
More...
|
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
1/26/2010
More...
|
Keryx Biopharmaceuticals (KERX) Cancer Drug Improves Survival in Mid-stage Trial
1/25/2010
More...
|
Poniard Pharmaceuticals, Inc. (PARD) Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
1/25/2010
More...
|
Transition Therapeutics Inc. (TTH.TO) Announces Results of a Phase 2 Study of TT-223 in Type 2 Diabetes Patients
1/25/2010
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) Provides Progress Update on Phase II Study of ANA598 in Hepatitis C Patients
1/22/2010
More...
|
Sunesis Pharmaceuticals, Inc. (SNSS) Completes Enrollment of Voreloxin Phase 1b/2 Combination Trial in Acute Myeloid Leukemia
1/21/2010
More...
|
Pharmasset, Inc. (VRUS) Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
1/21/2010
More...
|
AlphaRx Inc. (ALRX) and Gaia BioPharma Secure Phase I/II Manufacturer For GAI-122 and unveil Their Clinical Development Strategy
1/21/2010
More...
|
CytRx Corporation (CYTR) Announces 2010 Clinical and Development Milestones
1/21/2010
More...
|
Keryx Biopharmaceuticals (KERX) to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastrointestinal Cancers Symposium
1/21/2010
More...
|
BTG plc (BGC.L) Commences Phase IIa Study of Pleneva(TM) for Multiple Sclerosis
1/21/2010
More...
|
Lexicon Pharmaceuticals, Inc. (LXRX) Diabetes Drug Shows Promise in Mid-Stage Trial
1/20/2010
More...
|
MorphoSys AG Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis
1/19/2010
More...
|
Generex Biotechnology Corporation (GNBT) Makes Podium Presentation of Vaccine Technology Platform With Cancer & Influenza Updates at PepTalk 2010
1/19/2010
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
1/19/2010
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Announces Achievement of Clinical Milestone Under Its Collaboration with Merck KGaA (MKGAF.PK) for Cancer Treatment
1/19/2010
More...
|
Circassia Limited Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
1/19/2010
More...
|
PTC Therapeutics, Inc. Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
1/19/2010
More...
|
Novartis Corporation (NVS) and Antisoma PLC (ASM.L) Drug With Unique Disruption of Tumor Blood Flow Shows Promise
1/19/2010
More...
|
Biocryst Pharmaceuticals (BCRX)'s CTCL Pivotal Study Achieves Enrollment Target
1/15/2010
More...
|
International Medica Foundation Reaches Final Vaccination Milestone in Phase II Clinical Trial for Rotavirus Vaccine
1/14/2010
More...
|
AVIR Green Hills Biotechnology AG: Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
1/13/2010
More...
|
GENFIT Corp. (ALGFT): Potential for Combination of GFT505 with Statins
1/13/2010
More...
|
Acucela Inc. Launches ENVISION Clarity Trial; Initiates Phase 2 Clinical Trial of Oral Visual Cycle Modulator in Patients with Dry Age-Related Macular Degeneration
1/13/2010
More...
|
Threshold Pharmaceuticals, Inc. (THLD) Provides Clinical Development Update at J.P. Morgan Healthcare Conference
1/12/2010
More...
|
Antares Pharma, Inc. (ANTR) And Population Council Announce Positive Phase 2 Trial Results
1/12/2010
More...
|
FDA Grants Orphan Drug Status to Allon Therapeutics, Inc.'s Davunetide for Brain Disease
1/12/2010
More...
|
Cytheris SA Initiates INSPIRE 2, a Phase II Clinical Trial of Recombinant Human Interleukin-7 (CYT107) in Chronically Infected HIV Patients Who Fail to Achieve Optimal Immune Reconstitution under HAART Therapy
1/12/2010
More...
|
Nektar Therapeutics (NKTR) Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer
1/12/2010
More...
|
Nektar Therapeutics (NKTR) Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer
1/12/2010
More...
|
Penwest Pharmaceutical (PPCO) Announces Initiation of Phase IIa Clinical Trial of A0001 in Patients With Friedreich's Ataxia
1/11/2010
More...
|
Raptor Pharmaceutical Inc. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis Potential to Improve Treatment with Less Frequent Administration and Better Tolerability
1/11/2010
More...
|
Stem Cell Therapeutics (SSS.V) Announces Second Positive Review by Data Safety Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial and Provides Corporate Update
1/11/2010
More...
|
Facet Biotech Announces Enrollment of First Patient in Phase 2 Study of Elotuzumab in Patients With Relapsed Multiple Myeloma
1/11/2010
More...
|
Trubion Pharmaceuticals Inc. (TRBN) Announces Initiation of a Phase 2 Study of SBI-087 for the Treatment of Rheumatoid Arthritis (RA)
1/11/2010
More...
|
Sangamo BioSciences, Inc. (SGMO) Advances ZFP Therapeutic(TM) Pipeline
1/11/2010
More...
|
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
1/11/2010
More...
|
Protox Therapeutics Inc. (PRX.V) Reports Positive Phase2 Trial Results For Urological Drug
1/11/2010
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC)'s Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations
1/7/2010
More...
|
Poniard Pharmaceuticals, Inc. (PARD) Announces 2010 Goals for Picoplatin
1/7/2010
More...
|
Ardea Biosciences, Inc. (JOBS) Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat
1/7/2010
More...
|
Ardea Biosciences, Inc. Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat
1/7/2010
More...
|
NexBio, Inc. Initiates Phase II Trial of DAS181 (Fludase(R)*) for Treatment of Influenza, Including Pandemic Influenza A(H1N1)
1/7/2010
More...
|
VIVUS, Inc. (VVUS) Drug Qnexa Cuts Apnea in Small Trial; Shares Jump
1/7/2010
More...
|
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
1/6/2010
More...
|
Hybrigenics Receives Authorization To Dose Prostate Cancer Patients Twice Daily With Oral Inecalcitol
1/6/2010
More...
|
Phase II Clinical Trial of Gilead Sciences, Inc. (GILD)'s (JOBS) Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary Objective
1/6/2010
More...
|
OncoGenex Pharmaceuticals Inc. Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding
1/6/2010
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
1/6/2010
More...
|
NeoPharm (NEOL) Presents the Phase II Data of Liposome-Entrapped Paclitaxel (LEP) in Patients with Metastatic Breast Cancer
1/6/2010
More...
|
CytRx Corporation (CYTR) Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 as a Treatment for Advanced Pancreatic Cancer
1/6/2010
More...
|
VBL Therapeutics Initiates Phase 2 Clinical Trial of VB-201 in Patients with Psoriasis
1/5/2010
More...
|
China Aoxing Pharmaceutical Corp. (CAXG) Announces Successful Completion of Phase II Clinical Study of Novel Menstrual Pain Drug
1/5/2010
More...
|
Capstone Therapeutics (CAPS) Announces Completion of Enrollment for AZX100 Phase 2 Clinical Trial in Dermal Scarring Following Shoulder Surgery
1/5/2010
More...
|
EnVivo Pharmaceuticals, Inc. Enters Phase 2b Trials for Its EVP-6124 Compound in the Treatment of Schizophrenia
1/5/2010
More...
|
Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001
1/5/2010
More...
|
Pearl Therapeutics Announces Positive Results From Phase 2a Trial of Formoterol Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
1/4/2010
More...
|
Immutep S.A. Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
1/4/2010
More...
|
NovaBiotics Ltd Successful Completion of Phase IIa Clinical Development of its Nail Fungus Treatment, Novexatin(R)
1/4/2010
More...
|
Cyclacel Limited (CYCC) Announces Publication of Peer-Reviewed Journal Article Describing the Mechanism of Action of Seliciclib
12/30/2009
More...
|
BioNovo, Inc. (BNVI) Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
12/29/2009
More...
|
Resverlogix Corporation (RVX.TO) Commences Phase 2 Atherosclerosis Clinical Trial
12/23/2009
More...
|
Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) following failure of Gleevec(R) and Sutent(R)
12/23/2009
More...
|
Eisai Inc. (ESALF.PK): Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
12/22/2009
More...
|
Undisclosed Group Seeks to Discredit GENFIT Corp. (ALGFT)'s Clinical Drug Candidate GFT505
12/22/2009
More...
|
CPEX Pharmaceuticals Announces Completion of Enrollment in Phase 2a Clinical Trial of Nasulin(TM)
12/21/2009
More...
|
Flamel Technologies (FLML) Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection
12/18/2009
More...
|
Anadys Pharmaceuticals, Inc. (ANDS) Hepatitis C Drug Meets Key Study Goals
12/17/2009
More...
|
Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Non-Small Cell Lung Cancer
12/17/2009
More...
|
Amarillo Biosciences (AMAR) Issues Update on Australian Phase 2 Clinical Trial Testing Oral Interferon as Prevention Against Influenza
12/17/2009
More...
|
DURECT Corporation (DRRX) (JOBS) Says Anesthetic Shows Positive Results in Mid-Stage Trial
12/17/2009
More...
|
Auxilium Pharmaceuticals (AUXL) Announces Top Line Phase IIb XIAFLEX(TM) Peyronie's Results
12/16/2009
More...
|
ChemoCentryx, Inc. Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
12/16/2009
More...
|
Auxilium Pharmaceuticals (AUXL) Says Penile Curvature Treatment Meets Efficacy Goals
12/16/2009
More...
|
BioSpecifics Technologies Corporation (BSTC) Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease
12/16/2009
More...
|
Can-Fite BioPharma to Initiate Phase II Clinical Trial with CF101 for the Treatment of Glaucoma
12/15/2009
More...
|
Positive Phase IIb Topline Clinical Data for Celgene (CELG) Oral Compound Apremilast (CC-10004) Reported for Patients with Moderate-to-Severe Psoriasis
12/15/2009
More...
|
Generex Biotechnology Corporation (GNBT) Clarifies Previous Announcement of Breast Cancer Study Interim Results
12/15/2009
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Provides Update on Meeting With FDA to Discuss Pivotal Study Design for Sapacitabine
12/15/2009
More...
|
Advaxis, Inc. Announces Phase II Trial Collaboration with the National Cancer Institute
12/15/2009
More...
|
BioAlliance Pharma: Entry into Clinical Phase: Clonidine Lauriad(R) into Phase II and AMEP(TM) into Phase I
12/15/2009
More...
|
Elan Corporation PLC (ELN) and Transition Therapeutics Inc. (TTH.TO) Drop Top Drug Doses After Nine Alzheimer's Patient Deaths
12/15/2009
More...
|
Pfizer Inc. (PFE) Announces Neratinib Data In HER2 Positive Breast Cancer
12/14/2009
More...
|
Celldex Therapeutics, Inc. Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer
12/14/2009
More...
|
Sanofi-Aventis (France) (SASY.PA) Breast Cancer Drug Gets FDA Fast-Track Nod
12/14/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) Stops Lead Drug Trial Due To Liver Problems
12/14/2009
More...
|
Primary Endpoint Reached In Active Biotech AB's TASQ Phase II Clinical Trial In Prostate Cancer Patients
12/14/2009
More...
|
KeyNeurotek Pharmaceuticals Reports Breakthrough In The Treatment Of Patients With Severe Traumatic Brain Injury In A Phase IIa Study
12/14/2009
More...
|
Genentech (South SF) (RHHBY) Release: New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-Positive Breast Cancer
12/14/2009
More...
|
Incyte Corporation (INCY)'s Data from a Phase I/II Study Presented at the 32nd San Antonio Breast Cancer Symposium Suggest that INCB7839 in Combination with Trastuzumab May Improve Clinical Response Rates in HER2 Positive Patients with Advanced Metastatic Disease
12/14/2009
More...
|
Generex Biotechnology Corporation (GNBT) Presents Encouraging Interim Results of Phase II Breast Cancer Study
12/14/2009
More...
|
Cosmo Pharmaceuticals S.p.A.'s CB-03-01 Phase II Pilot Study In Acne Demonstrates Superiority Over Retin A(R)
12/11/2009
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI)'s Zevalin(R) (Ibritumomab Tiuxetan) Demonstrated Activity in Several Investigational Phase 2 Trials Presented at the 51st Annual Meeting of the American Society of Hematology
12/11/2009
More...
|
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
12/11/2009
More...
|
ThromboGenics NV Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
12/11/2009
More...
|
iCo Therapeutics Inc. Provides Phase 1 DME Clinical Trial Update and Phase 2 Trial Guidance
12/11/2009
More...
|
Neurocrine Biosciences, Inc. (NBIX) Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
12/10/2009
More...
|
XOMA (US) LLC (XOMA) Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference
12/10/2009
More...
|
Targacept, Inc. (TRGT) Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia
12/10/2009
More...
|
Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
12/10/2009
More...
|
Sangamo BioSciences, Inc. (SGMO) Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium Early Data Demonstrates Improvement in Muscle Function with SB-509 Treatment Compared to Historic Controls
12/9/2009
More...
|
Knopp NeuroSciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS
12/9/2009
More...
|
Oxagen Limited Announces Completion of Recruitment in Phase IIb Dose Range-Finding Clinical Trial in New Oral Treatment for Asthma
12/9/2009
More...
|
Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
12/9/2009
More...
|
Sangamo BioSciences, Inc. (SGMO) Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium Early Data Demonstrates Improvement in Muscle Function with SB-509 Treatment Compared to Historic Controls
12/9/2009
More...
|
Genzyme Corporation (GENZ)'s Mozobil Shows Promise in Chemosensitization
12/8/2009
More...
|
Geron Corporation (GERN) Presents Interim Clinical Data on Its Telomerase Vaccine at the 2009 American Society of Hematology Meeting
12/8/2009
More...
|
Cytheris SA Announces Initiation of CONVERT, a Phase I/IIa Study of Recombinant Human Interleukin-7 (CYT107) in Combination with Antiviral Therapy and Vaccination for Treatment of Chronic Hepatitis B Virus
12/8/2009
More...
|
Neovacs SA Initiates a Phase II Clinical Trial of TNFa Kinoid in Rheumatoid Arthritis Patients Failing TNFa Monoclonal Antibody Therapy
12/8/2009
More...
|
Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
12/8/2009
More...
|
Gentium S.p.A. Announces Final Clinical Trial Results for Defibrotide Presented at the American Society of Hematology Conference
12/8/2009
More...
|
Sunesis Pharmaceuticals, Inc. (SNSS) Presents Positive Phase 2 Clinical Data of Voreloxin in Acute Myeloid Leukemia at the American Society of Hematology 2009 Annual Meeting
12/8/2009
More...
|
Phase IIa Clinical Data Confirms Potential of Allon Therapeutics, Inc.'s Davunetide as a Treatment for Cognitive Impairment in Schizophrenia Patients
12/8/2009
More...
|
Ohr Pharmaceutical (OHRP) Presents New Interim Phase 2 Clinical Data Showing Its OHR/AVR118 Drug to Be Safe, Effective Treatment of Severe Wasting Disorder (Cachexia) in Late Stage Cancer Patients
12/8/2009
More...
|
Millennium: The Takeda Oncology Company Release:The Addition of VELCADE(R) (Bortezomib) for Injection to Novel Combination Delivers Promising Results in Patients with Non-Hodgkin's Lymphoma
12/8/2009
More...
|
BioAlliance Pharma: Doxorubicin Transdrug(R): Significant Increased Survival Rate In Patients With Advanced Hepatocellular Carcinoma Treated In A Phase II Clinical Trial
12/8/2009
More...
|
CytRx Corporation (CYTR) Says Preliminary Results of Cancer Drug Shows Promise
12/8/2009
More...
|
Cyclacel Limited (CYCC) Reports Phase 2 Sapacitabine Data in Acute Myeloid Leukemia and Myelodysplastic Syndromes at 2009 American Society of Hematology Annual Meeting
12/7/2009
More...
|
Hana Biosciences, Inc. (HNAB) Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
12/7/2009
More...
|
CytRx Corporation (CYTR) Announces Positive Phase 2 Results For Tamibarotene in the Treatment of Relapsed Acute Promyelocytic Leukemia
12/7/2009
More...
|
Pharmacyclics, Inc. (PCYC) Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
12/7/2009
More...
|
Onyx Pharmaceuticals, Inc. (ONXX) Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability Pivotal Trial Fully Enrolled - Full Data Anticipated in 2010
12/7/2009
More...
|
Celgene International Sárl (CELG): Phase II Data Evaluating REVLIMID(R) + Rituximab in Relapsed Patients with Chronic Lymphocytic Leukaemia Presented at American Society of Hematology
12/7/2009
More...
|
Celator Pharmaceuticals, Inc. Presents Interim Data from Phase 2 Study of CPX-351 in Newly Diagnosed AML at American Society of Hematology Meeting
12/7/2009
More...
|
Antisoma PLC (ASM.L)'s AS1413 Regimen Yields High Response Rate And Durable Responses In Patients With Secondary AML, A Poor-Risk Population Underserved By Current Treatment Options
12/7/2009
More...
|
Facet Biotech and Bristol-Myers Squibb Company (BMY) Report Promising Phase I/II Interim Data for Elotuzumab in Patients With Relapsed Multiple Myeloma
12/7/2009
More...
|
Keryx Biopharmaceuticals (KERX) Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
12/7/2009
More...
|
Clavis Pharma ASA: Positive Phase II Clinical Data For Clavis Pharma's Elacytarabine Presented At American Society of Hematology Annual Meeting
12/7/2009
More...
|
Q-Med AB and Oceana Therapeutics Take Major Step Towards SOLESTA(TM) US Regulatory Filing
12/7/2009
More...
|
Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine
12/7/2009
More...
|
Onyx Pharmaceuticals, Inc. (ONXX) (JOBS) Drug Shows Promise in Multiple Myeloma Study
12/7/2009
More...
|
Oxygen Biotherapeutics, Inc. (OXBO) Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
12/4/2009
More...
|
Hyperion Therapeutics Enrolls First Patient in Phase II Hepatic Encephalopathy Trial
12/3/2009
More...
|
Neurologix, Inc. Completes All Surgical Procedures in Its Clinical Trial for Parkinson's Disease
12/3/2009
More...
|
Cubist Pharmaceuticals, Inc. (CBST) Closes Enrollment Early in CONSERV(TM)-1 and CONSERV-2 Ph. 2 Trials for CB-500,929 (Ecallantide), in Development as Therapy to Reduce Bleeding in On-Pump Cardiac Surgery
12/3/2009
More...
|
PharmaSurgics to Begin Phase II Clinical Trial for Prevention of Post-Surgical Adhesions
12/3/2009
More...
|
Lightlake Therapeutics Inc. Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
12/3/2009
More...
|
Cubist Pharmaceuticals, Inc. (CBST) (JOBS) Halts Enrollment in Trials on Safety Concerns
12/3/2009
More...
|
Novavax, Inc. (NVAX) Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
12/2/2009
More...
|
Significant Potential of Late- and Mid-Stage Novartis Corporation (NVS) Hematology Portfolio to be Showcased at Upcoming American Society of Hematology Meeting
12/2/2009
More...
|
Dermagen Inc. Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
12/2/2009
More...
|
Peregrine Pharmaceuticals, Inc. (PPHM) Completes Patient Enrollment In Cotara(R) Dose Confirmation And Dosimetry Brain Cancer Trial
12/2/2009
More...
|
New Data on Bristol-Myers Squibb Company (BMY) Oncology Compounds to be Featured in Oral Presentations at 51st Annual Meeting of the American Society of Hematology
12/2/2009
More...
|
Optinose Announces Study Results Of Intranasal Device For Treating Chronic Rhinosinusitis With Nasal Polyps
12/2/2009
More...
|
BioMarin Pharmaceutical Inc. (BMRN) Autoimmune Disease Drug Gets Orphan Status
12/1/2009
More...
|
Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America
12/1/2009
More...
|
Ardea Biosciences, Inc. Reports Positive Results from Combination of RDEA594 and Febuxostat
12/1/2009
More...
|
Provectus Pharmaceuticals Inc. Announces Preliminary Phase 2 Data For PH-10 in its Psoriasis and Atopic Dermatitis Trials
12/1/2009
More...
|
Cytokinetics, Inc. (CYTK) Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2009 American Society of Hematology Annual Meeting and Exposition
12/1/2009
More...
|
Agennix AG Announces Positive Results With Talactoferrin in Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Severe Sepsis
12/1/2009
More...
|
Ohr Pharmaceutical (OHRP) Announces Presentation of Interim Phase II Cachexia Data
12/1/2009
More...
|
Sunesis Pharmaceuticals, Inc. (SNSS) to Host Conference Call on Tuesday, December 8th to Discuss New Phase 2 Voreloxin Data Presented at American Society of Hematology
12/1/2009
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC) to Host Conference Call on Monday, December 7 to Discuss New Phase 2 Sapacitabine Data to be Presented at American Society of Hematology
12/1/2009
More...
|
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor
11/30/2009
More...
|
Novavax, Inc. (NVAX) Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
11/30/2009
More...
|
Lorus Therapeutics Inc. (LRP) Announces Positive Result in Its Phase II Clinical Study of LOR-2040 in Acute Myeloid Leukemia (AML)
11/30/2009
More...
|
Biovitrum AB's Kiobrina(TM) Shows Positive Phase II Results In Preterm Infants
11/25/2009
More...
|
Sucampo Pharmaceuticals, Inc. Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG
11/25/2009
More...
|
Ipsen Initiates an Advanced Endometrial Cancer Program with BN83495, its First-in-Class Steroid Sulfatase (STS) Inhibitor
11/25/2009
More...
|
AEterna Zentaris (AEZS) Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
11/24/2009
More...
|
ARCA Discovery Inc. Gets Fast-Track Status for Heart Drug
11/24/2009
More...
|
CytRx Corporation (CYTR) Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Soft Tissue Sarcomas
11/24/2009
More...
|
Valeant Pharmaceuticals International (VRX) May Fall if New Drug Disappoints-Barron's
11/24/2009
More...
|
Cephalon, Inc. (CEPH) Delays Ception Deal After Mixed Drug Data
11/24/2009
More...
|
Raptor Pharmaceutical Inc. Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis Goal of Trial Achieved Demonstrating Potentially Less Frequent Administration Using Lower Daily Dose
11/23/2009
More...
|
Provectus Pharmaceuticals Inc. Release: Interim Phase 2 Survival Data for PV-10 Shows Markedly Longer Overall and Disease Specific Survival for Subjects Responsive to PV-10
11/23/2009
More...
|
Lexicon Genetics Incorporated (LEXG) to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
11/23/2009
More...
|
Pharmasset, Inc. (VRUS) Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
11/23/2009
More...
|